The Uab Research Foundation

Emory University

Children's Healthcare of Atlanta, Inc.

Benaroya Research Institute

Max Dale Cooper

Brantley R Herrin

Matthew N Alder

Christopher B Doering

H Trent Spencer

Zeev Pancer

Chris Amemiya

G Larry Gartland

Rudolf Ehrhardt

Goetz R A Ehrhardt

Randall S Davis

Goetz Ehrhardt

Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs). More particularly, disclosed are a variety of antigen specific polypeptides, including soluble, monoclonal, and multivalent forms, as well as methods of using the polypeptides, antibodies that bind the antigen specific polypeptides, and nucleic acids, vectors and expression systems that encode the polypeptides. Antigen specific polypeptides that selectively bind pathogens, like anthrax, and carbohydrates, like blood group determinants, are specifically disclosed.

Methods and compositions related to soluble monoclonal variable lymphocyte receptors of defined antigen specificity

This disclosure relates to variable lymphocyte receptors (VLRs) modifications such as humanized sequences and polypeptides comprising such sequences that specifically bind a target molecule and uses related thereto. In certain embodiments, the disclosure relates to recombinant polypeptide VLRs disclosed herein and variants thereof. In certain embodiments, this disclosure relates to treating or preventing a disease or condition comprising administering an effective amount of a recombinant polypeptide or variant disclosed herein to a subject in need thereof.

Recombinant vector and expression system comprising a nucleic acid encoding a variable lymphocyte receptor (VLR)

This disclosure relates to recombinant cellular expression of chimeric proteins with peptide sequences derived from lymphocyte receptors and uses for treating cancer. In certain embodiments, the disclosure relates to a recombinant vector comprising a nucleic acid that encodes a chimeric protein with a segment with a targeting moiety based on a variable lymphocyte receptor (VLR) capable of binding a tumor associated antigen and a segment with a T cell signal transduction subunit. In certain embodiments, the recombinant vectors are used in immune based cancer treatments.

Expression of chimeric polypeptide with variable lymphocyte receptors on immune cells and uses for treating cancer

Modified recombinant variable lymphocyte receptors (VLR)

The invention relates to members of the Fc receptor homolog (FcRH) subfamily, as well as fragments and variants thereof. Each FcRH is a Type I transmembrane receptor, preferably, comprises an extracellular region, a transmembrane region, and a cytoplasmic region. The cytoplasmic region preferably comprises one or more immunoreceptor tyrosine-based inhibitory or activation motifs ('ITIMs' or 'ITAMs). The invention provides polypeptides, nucleic acids, vectors, expression systems, and antibodies and antibody fragments related to the FcRHs as well as uses thereof. Such uses include uses in the diagnosis and treatment of a malignancy of hematopoietic cell lineage or an inflammatory or autoimmune disease in a subject and in the modulation of a humoral immune response in a subject.

Members of the FC receptor homolog gene family (FcRH1-3,6) related reagents and uses thereof

Disclosed are compositions and methods related to variable lymphocyte receptors (VLRs).

Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof

Variable lymphocyte receptors

Members of the FC receptor homolog gene family (FCRH1-3, 6), related reagents, and uses thereof

Growing community of inventors

Atlanta, GA, United States of America

Max Dale Cooper